Linked Life Data

2336872

Source:http://linkedlifedata.com/resource/pubmed/id/2336872

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1990-6-11
pubmed:abstractText
Three hundred and twenty-two (322) persons with severe mental handicaps were given plasma-derived hepatitis B vaccine (20 micrograms dose at 0, 1 and 6 months). Following the third injection, 95% of the vaccinees were positive for anti-HBs, while 92% achieved a protective level of antibody (greater than or equal to 10 mIU ml-1) with a geometric mean titre of 2568 mIU ml-1. Females responded better than males. Antibody responses declined with increasing age in both sexes, but they were not significantly influenced by body weight. Persistence of antibody in responders was followed over 4 years. The proportion of responders maintaining greater than or equal to 10 mIU ml-1 was a function of initial antibody titre but was not significantly affected by sex, age or body weight. Overall, 76% of the responders are estimated to have greater than or equal to 10 mIU ml-1 of anti-HBs 4 years after the first injection of vaccine.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
111-4
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Development and persistence of antibody in a high risk institutionalized population given plasma-derived hepatitis B vaccine.
pubmed:affiliation
Merck Sharp & Dohme Research Laboratories, West Point, PA 19486.
pubmed:publicationType
Journal Article